Matrilysin (MMP-7) is thought to contribute to invasive growth and metastasis of colon carcinoma and many other human cancers. The present study demonstrates that treatment of human colon carcinoma cells with active matrilysin induces cell aggregation in vitro and promotes liver metastasis in nude mice. When two kinds of colon carcinoma cell lines were incubated with active matrilysin, this enzyme efficiently bound to the cell surface and induced loose cell aggregation, which led to E-cadherinmediated tight cell aggregation. Synthetic MMP inhibitors inhibited both the membrane binding of matrilysin and matrilysin-induced cell aggregation, while TIMP-2 inhibited only the cell aggregation. Two other active MMPs, stromelysin and gelatinase A, neither bound to cell membrane nor induced cell aggregation. Tumor cells in loose cell aggregates could reaggregate even after they were freed from matrilysin and dispersed. When injected into the spleen of nude mice, the tumor cells in the stable aggregates produced much larger metastatic nodules in the livers than control cells and those in the loose aggregates. These results suggest that matrilysin may enhance metastatic potential of tumor cells by processing a cell surface protein(s) and thereby inducing loose and then tight aggregation of tumor cells.
Introduction
Matrix metalloproteinases (MMPs) are believed to play key roles in tumor invasion and metastasis as well as tissue remodeling and differentiation (Werb, 1997; Nagase and Woessner, 1999) . They degrade extracellular matrix (ECM) proteins in the basement membrane and underlying stroma, thereby facilitating tumor growth, invasion, and metastasis. In addition, recent studies have provided evidence showing that the biological functions of various membrane or ECM molecules are modulated by the actions of several MMPs, including gelatinase A (MMP-2) (Giannelli et al., 1997) , gelatinase B (MMP-9) (Yu and Stamenkovic, 2000) , stromelysin (MMP-3) (Agnihotri et al., 2001) , and matrilysin (MMP-7) (Abdel-Ghany et al., 2001) . Many metalloproteinases including MMPs and ADAMs (a disintegrin and metalloproteinases) are likely to regulate cellular functions by activating, inactivating, or releasing membrane proteins (Caterson et al., 2000) . Trypsin, a matrix serine proteinase, has been reported to induce aggregation of Colo 205 cells (Aono et al., 1999) and to activate PAR-2 receptor on gastric carcinoma cells, promoting cell adhesion to ECM proteins (Miyata et al., 2000) .
Matrilysin, which is the smallest member of the MMP family, is one of a few MMPs which are overexpressed by carcinoma cells rather than stromal cells Nagashima et al., 1997) . Some recent studies have shed a new light on the action of matrilysin on the cell surface. Matrilysin cleaves cell adhesion molecules including integrin b4 (von Bredow et al., 1997) . It activates intestinal a-defensin, and this may be involved in a host defense mechanism (Wilson et al., 1999) . Matrilysin is colocalized with tissue factor (TF) and TF pathway inhibitor (TFPI), and it may affect the TFmediated coagulation of leukocytes by cleaving TFPI (Belaaouaj et al., 2000) . Among more than 20 MMPs, matrilysin appears to be one of the most important MMPs in human colon cancers because it is almost always overexpressed in colon cancers (Yoshimoto et al., 1993) . Expression of matrilysin is correlated with tumor malignancy and metastasis, especially liver metastasis of colon cancer (Ishikawa et al., 1996; Adachi et al., 1999) . However, detailed actions of matrilysin in the process of tumor invasion and metastasis have not been clarified. It has recently been reported that matrilysin contributes to tumor malignancy by cleaving cell surface proteins, such as Fas ligand and E-cadherin (Davies et al., 2001; Mitsiades et al., 2001; Noe et al., 2001) . Another study suggested that degradation of IgG by matrilysin may protect tumor cells from the immune system (Gearing et al., 2002) .
It was previously found that an antisense oligonucleotide to the matrilysin gene suppresses the metastasis of human colon carcinoma cells from the spleen to the liver in an experimental metastasis model with nude mice (Hasegawa et al., 1998) . In the present study, we examined the direct action of matrilysin to tumor cells and found that treatment of human colon carcinoma cells with active matrilysin causes prominent morphological change of the cells in vitro and promotes their liver metastasis in nude mice.
Results

Induction of aggregation of colon carcinoma cells by matrilysin
To investigate direct effect of matrilysin on tumor cells, two kinds of human colon carcinoma cell lines, WiDr and Colo 201, were treated with active matrilysin under various culture conditions. This attempt revealed that active matrilysin induced marked morphological change of these carcinoma cell lines especially on polyhydroxylethyl-methacrylate (poly-HEMA)-coated culture dishes or bacterial culture dishes with serum-free medium, where cells loosely attached onto the plastic surface without spreading. When WiDr cells, which secreted a low level of pro-matrilysin, were incubated with exogenous active matrilysin (1 mg/ml) in poly-HEMA-coated dishes for 48 h, they formed large spheroidal cell aggregates or cell clusters ( Figure 1A , left). In the absence of matrilysin treatment, the cells produced far smaller cell aggregates ( Figure 1A , right).
When active matrilysin was added to the culture of Colo201 cells in poly-HEMA-coated dishes, they formed prominent cell aggregates even at 3 h ( Figure 1B (a-c) ). In the absence of matrilysin treatment, these cells did not form cell aggregates and existed mostly as single, floating cells for 24 h ( Figure 1B (d-f ) ). The matrilysin-induced cell aggregation was not significantly affected by the presence of 10% fetal bovine serum (FBS) ( Figure 1C ). The latent form of matrilysin (pro-matrilysin) did not have such an effect on either cell type (data not shown). As Colo 201 did not express matrilysin and appeared more sensitive to matrilysin, this cell line in the poly-HEMA-coated dishes with serum-free medium was routinely used in the following cell aggregation assays.
The matrilysin-induced aggregation of Colo 201 cells was almost completely blocked by the presence of tissue inhibitor of metalloproteinases-2 (TIMP-2) or the synthetic MMP inhibitor KB8301 (Figure 2A and B) . When active forms of two other MMPs, stromelysin and gelatinase A, were assayed for the ability to induce the cell aggregation, they were unable to induce cell aggregation at the molar concentration used for matrilysin ( Figure 2C ).
Cell surface binding and proteolytic activity of matrilysin
The results shown above suggest that matrilysin may bind to cell surface and hydrolyse a cell surface protein(s). First, the binding of matrilysin to cell surface was tested by Western blotting analysis of the membrane fraction from the matrilysin-treated Colo 201 cells. The antimatrilysin antibody clearly detected the active form of matrilysin in the cell membrane fraction Figure 3a ). This analysis also showed that promatrilysin could not bind to the cell membrane. The binding of active matrilysin to cell surface was confirmed by the immunofluorescense staining of the matrilysin-treated cells (Figure 3b ).
There is a report showing that promatrilysin binds to heparan sulfate proteoglycan on cell surface in rat uterine cells (Yu and Woessner, 2000) . To characterize the membrane binding of matrilysin, effects of three MMP inhibitors and heparin were examined in Colo 201 cells (Figure 3c ). Two hydroxamate MMP inhibitors, KB8301 and TAPI, effectively prevented the binding of matrilysin to cell membrane. In contrast, the natural inhibitor TIMP-2 did not inhibit the membrane binding of matrilysin, in spite of its inhibitory activity against the matrilysin-induced cell aggregation (Figure 2A ). This suggests that not only the cell binding of matrilysin but also its activity is important for inducing cell aggregation. In this analysis, heparin had no effect on the membrane binding of matrilysin, suggesting that were incubated without (lane 3), or with active matrilysin (1 mg/ml) (lanes 1 and 4) or promatrilysin (1.5 mg/ml) (lanes 2 and 5) for 24 h. After washing the cells twice, they were homogenized, and the membrane fraction was collected. The active form and proform of matrilysin in the conditioned medium (unbound) and the membrane fraction (bound) were detected by Western blotting with the antimatrilysin monoclonal antibody. (b) Immunofluorescent staining of membrane-bound matrilysin. Colo 201 cells were treated without (control) or with (matrilysin) biotinylated matrilysin for 24 h. The membrane-bound matrilysin was detected by FITC as described under Materials and methods. (c) Effects of MMP inhibitors and heparin on membrane binding of matrilysin. Colo 201 cells were incubated with active matrilysin in the absence (Control) or presence of 2 mM KB8301, 2 mM TAPI, 0.2 mM TIMP-2, or 1 mg/ml heparin for 6 h, and then the membrane-bound matrilysin was analysed as described above. (d) Activity of matrilysin bound to cell membrane. Cell membrane fraction was prepared from Colo 201 cells that had been incubated with active matrilysin for 6 h. The membrane fraction corresponding to the indicated number of cells was suspended in 200 ml of 50 mM TrisHCl buffer (pH 7.5) containing 150 mM NaCl, 0.01% Brij 35 and 0.01% BSA, and then incubated with the synthetic substrate 3163v (1 mM) in the absence () or presence (m) of 10 mM KB8301 for 40 min, as reported previously (Higashi and Miyazaki, 2003) . Each point represents the mean of the relative enzyme activities in the triplicate cultures. Bars, s.d. (e) Binding of three kinds of active MMPs to cell membrane. Colo 201 cells were incubated with 0.05 mM of gelatinase A (Gel.A), stromelysin (Strom.), or matrilysin (MAT) for 6 h. After the incubation, the conditioned media (lane 1) and membrane fractions (lane 2) were prepared as above and analysed by zymography on a gelatin-containing polyacrylamide gel (10%) for detection of gelatinase A or a casein-containing gel (14%) for stromelysin and matrilysin, according to the method reported before . Arrows indicate the bands of MMPs Induction of tumor cell aggregation by matrilysin M Kioi et al heparan sulfate proteoglycan is not a receptor of mature matrilysin. The membrane fraction containing matrilysin could hydrolyse a synthetic substrate for matrilysin, and this activity was inhibited by KB8301, indicating that membrane-bound matrilysin maintained its enzyme activity ( Figure 3d ).
When active forms of matrilysin, stromelysin and gelatinase A were incubated with Colo 201 cells, only matrilysin was detected in the membrane fraction as analysed by zymography ( Figure 3e ). The binding of active matrilysin to cell membrane was also shown in WiDr cells (data not shown).
Next, we examined degradation of membrane proteins by matrilysin treatment. Cell surface proteins of Colo 201 were biotinylated and then incubated with matrilysin. The matrilysin treatment released some membrane proteins into culture medium ( Figure 4a ). Analysis of E-cadherin by immunoprecipitation showed that mature E-cadherin of 120 kDa was cleaved into two truncated forms of 105 and 85 kDa on the cell membrane ( Figure 4b ). However, the degradation of E-cadherin was scarcely affected by the matrilysin treatment ( Figure 4b ). The analysis of E-cadherin in the conditioned medium also showed that this protein was released as an 80-kDa soluble form into culture medium at a high level (Figure 4c ). The amount of Ecadherin in the culture medium again did not significantly change after the matrilysin treatment. Essentially, the same results were obtained with WiDr cells (data not shown). These results indicate that E-cadherin on cell surface is constitutively cleaved by an endogenous proteinase, but it is poorly susceptible to exogenous matrilysin at least in Colo201 and WiDr cells.
We also examined the possibility that some ECM proteins partially hydrolysed or cell surface proteins released by the matrilysin treatment might induce cell aggregation. However, neither the ECM proteins deposited by the matrilysin-treated culture of Colo 201 cells nor the conditioned medium from the same culture induced cell aggregation (data not shown). ) were treated at 41C for 30 min with the biotinylation reagent Biotin-AC5-Osu (Wako, Osaka, Japan) and then incubated without (None) or with (MAT) matrilysin (1 mg/ml) for 27 h. From these cultures, the membrane fraction (Membr.) and the conditioned medium (CM) were prepared. The biotinylated proteins in these fractions were separated by SDS-PAGE, transferred onto a nitrocellulose membrane, and detected with the avidin-conjugated alkaline phosphatase. 
Two types of cell aggregation induced by matrilysin
In an attempt to characterize the matrilysin-induced cell aggregation, we found that the cell aggregation proceeded in two steps, initial loose aggregation and subsequent stable aggregation. Colo 201 cells formed small cell aggregates within one h after the addition of matrilysin, and the size of cell aggregates was gradually increased by prolonged incubation, reaching the maximum level at 12 h ( Figure 1B) . Most of the cell aggregates formed by 6 h were easily dispersed into single cells by pipetting ( Figure 5A and B) . When the matrilysin treatment was continued beyond 6 h, the initial loose cell aggregates gradually condensed and hardened, and at 24 h the majority of the cells remained in cell aggregates after pipetting. Thus, these experiments discriminated between the initial loose cell aggregation (IA), which had weak cell-cell interaction and was completely dispersed by pipetting, and the stable cell aggregation (SA), which had stronger cell-cell interaction resistant to pipetting.
Cell-bound matrilysin in loose aggregates could be released by treating the cells with the MMP inhibitor KB8301 but not TIMP-2 (Figure 6a ). When the loose cell aggregates were freed from matrilysin by the treatment with KB8301 and dispersed into single cells by pipetting, these cells could reaggregate during further incubation (Figure 6b ). Reaggregation also occurred when the loose cell aggregates were dispersed and incubated in the presence of KB8301 (data not shown). This implies that a matrilysin-cleaved membrane protein(s), but not matrilysin itself, induces the loose cell aggregation.
Role of E-cadherin in cell aggregation
To examine the possible participation of E-cadherin in the matrilysin-induced cell aggregation, we utilized a function-blocking anti-E-cadherin monoclonal antibody. The anti-E-cadherin monoclonal antibody did not affect the initial loose aggregation but efficiently blocked the stable aggregation ( Figure 7A ). When the two types of cell aggregates were subjected to immunohistochemistry with the anti-E-cadherin monoclonal antibody, the immunoreactivity on the cell membrane was stronger in the stable aggregates than the initial loose aggregates ( Figure 7B ). These results suggest that matrilysin initializes loose cell aggregation by cleaving a cell surface protein(s) and the subsequent activation of the E-cadherin-dependent cell-cell adhesion system produces the stable aggregation. 6 per 35-mm dish) were incubated with (MAT) or without (None) matrilysin (1 mg/ml) for 6 h. The matrilysin-treated cells were further incubated for 1 h with 2 mM KB8301 (KB8301) or 0.2 mM TIMP-2 (TIMP-2). Membrane fractions were prepared from these cells, and matrilysin in the fractions was analysed as described in Figure 3a. (b) Reaggregation of loosely aggregated cells. Colo 201 cells were treated with matrilysin, and the membrane-bound matrilysin was removed by 2 mM KB8301, as described above. These cells were dispersed by pipetting and then further incubated in the absence of matrilysin and KB8301 for 1 h: Left, after matrilysin treatment; center, after dispersion; right, after incubation for reaggregation Figure 7 Contribution of E-cadherin to matrilysin-induced cell aggregation. (A) Effect of anti-E-cadherin monoclonal antibody on matrilysin-induced loose and stable aggregations. Colo 201 cells were incubated with matrilysin in the absence (None) or presence of the function-blocking anti-human E-cadherin monoclonal antibody (1 mg/ml) (E-Cad Ab), or mouse IgG (1 mg/ml) (mouse IgG) for 3 h or 24 h. Cell aggregation was determined before or after pipetting. Closed column, loose cell aggregation formed by the 3-h incubation as determined before pipetting; open column, stable aggregation formed by the 24-h incubation as determined after pipetting. Bars, s.d. (B) Localization of E-cadherin on matrilysininduced loose and stable cell aggregates. Colo 201 cells were incubated with matrilysin for 3 h (a) or 24h (b), and the cell aggregates were subjected to immunofluorescent staining with the anti-E-cadherin monoclonal antibody as described under the Material and methods
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Effect of matrilysin on metastasis of cancer cells in nude mice
As described above, matrilysin induces marked morphological change of colon carcinoma cells. This might affect the metastatic ability of the carcinoma cell lines. To test this possibility, WiDr cell line was used, because Colo 201 cells actually did not produce liver metastasis in a nude mouse model. WiDr cells were incubated with matrilysin for 3 or 24 h, and then injected into the spleen of nude mice. All mice injected with the cells that had been treated with matrilysin for 3 or 24 h produced metastatic foci in the livers, while 67% of the control group without matrilysin treatment produced metastatic foci (Figure 8a and b) . When the tumor size in the liver was compared, there was a clear difference among the three groups. The WiDr cells after 24-h matrilysin treatment produced over four times larger tumors in the liver than those after 3-h matrilysin treatment or the control mice (Figure 8c ; Po0.0002). There was a far smaller difference between the control cells and the cells with the short matrilysin treatment (P ¼ 0.01).
To get a clue to the mechanism how matrilysin treatment increases the metastatic ability of tumor cells, we examined effect of matrilysin treatment on cell growth and death in anchorage-independent culture conditions. Regardless of matrilysin treatment, WiDr cells grew well in suspension culture with methylcellulose in serum-containing medium (data not shown). However, matrilysin treatment had a significant effect on the cell survival in serum-free methylcellulose medium. WiDr cells stably aggregated by matrilysin treatment for 24 h grew slightly in the serum-free medium, whereas the control cells and the loosely aggregated cells after 3-h matrilysin treatment underwent cell death (Figure 9 ). The cell death was more rapid in the control than in the 3-h-treated cells. The increased ability to survive under anchorage-independent conditions may be one of the reasons for the high metastatic ability of matrilysin-treated cells.
Discussion
Recent studies have suggested that cell surface binding of secreted MMPs might regulate the functions of cell surface proteins and ECM proteins (Brooks et al., 1996; Chen, 1996; Takahashi et al., 1998) . The present study demonstrates that treatment of human colon carcinoma cells with matrilysin induces notable aggregation, or clustering, of the cancer cells in vitro and enhances their liver metastasis in nude mice. Experimental results suggest that matrilysin first binds to the cell membrane of the carcinoma cells and induces loose cell aggregation and then E-cadherin-mediated tight cell aggregation.
It has recently reported that rat promatrilysin binds to heparan sulfate proteoglycan on the surface of rat uterine cells (Yu and Woessner, 2000; Yu et al., 2002) . In the present study, only the active form of matrilysin efficiently bound to the tumor cell membrane, and heparin did not inhibit the membrane binding of matrilysin. Therefore, the cell surface receptor for active matrilysin on the human carcinoma cells detected in this study seems different from that for promatrilysin on the Induction of tumor cell aggregation by matrilysin M Kioi et al rat uterine cells. The membrane binding of matrilysin was inhibited by synthetic hydroxamate inhibitors but not by TIMP-2. We confirmed that matrilysin bound to the membrane still had enzyme activity. These results suggest that the membrane receptor of matrilysin is not a TIMP-like MMP inhibitor. Although TIMP-2 did not inhibit the membrane binding of matrilysin, it completely blocked the cell aggregation. When tumor cells in the loose cell aggregates were dispersed and freed from matrilysin by the KB8301 treatment, they reaggregated by further incubation. These observations indicate that proteolytic action of matrilysin rather than its presence on cell surface is important for inducing initial loose aggregation. On the other hand, matrilysin promoted detachment of WiDr cells from substrate. However, since Colo201 cells hardly attached to poly-HEMAcoated dishes even in the absence of matrilysin, the detachment step appears not to be a key step of matrilysin action at least in these experimental conditions. In vivo, however, the cell detachment promoted by matrilysin-dependent degradation of ECM proteins may also be important for tumor metastasis.
Two synthetic MMP inhibitors, KB8301 and TAPI, inhibited both the binding of matrilysin to cell surface and cell aggregation. Among the three MMPs tested (matrilysin, stromelysin and gelatinase A), only matrilysin bound to cell surface and induced cell aggregation, whereas the others neither bound to cell surface nor induced cell aggregation. These results may imply that the binding of active matrilysin to cell surface is also important for inducing cell aggregation, although persistent binding of matrilysin to the cell surface is not required for the loose aggregation (Figure 6b ). It is speculated that the membrane binding of matrilysin allows the effective cleavage of some membrane proteins. Although the mechanism by which active matrilysin binds to cell surface, keeping its proteolytic activity remains unknown, our results suggest that some specific aminoacid residues in the substrate-binding site of matrilysin, but not in its catalytic site, may be responsible for the membrane binding of matrilysin. Recent analyses of the crystal structures of MMP/ inhibitor complexes have made it possible to identify amino acid residues that are specifically found in the substrate-binding site of active matrilysin (Browner et al., 1995; Welch et al., 1996) . Some of these amino acid residues may be essential for the membrane binding of matrilysin and interact with the synthetic MMP inhibitors but not TIMP-2. By preparing recombinant matrilysins with point mutation in the substrate-binding site, we are currently investigating the mechanism for the membrane binding of matrilysin. We have succeeded in obtaining a matrilysin mutant that is enzymatically active but cannot bind to cell surface (Kioi et al., unpublished data).
Recent studies have shown the cleavage of cell surface proteins by matrilysin and its possible contribution to tumor malignancy (Davies et al., 2001; Mitsiades et al., 2001; Noe et al., 2001) . Especially, E-cadherin was considered to be an important target of matrilysin in tumor cells. Dysfunction of the E-cadherin cell adhesion system is known to be related with invasive and metastatic potentials of human cancers (Takeichi, 1993) . Our present study strongly suggests that proteolysis of membrane protein(s) by matrilysin may be a key step to induce cell aggregation. Although some membrane proteins were released by the matrilysin treatment, we could not identify the target protein responsible for the cell aggregation. However, our results clearly indicate that E-cadherin is not a target protein of matrilysin. E-cadherin was constantly cleaved and released from cell surface by an endogenous proteinase, but matrilysin treatment did not affect the shedding of E-cadherin from cell surface. The discrepancy on E-cadherin degradation by matrilysin between the past studies and the present study may derive from differences in the cell type and experimental conditions used in these studies.
E-cadherin seemed rather critical for the matrilysininduced stable aggregation. We have examined effects of various metabolic inhibitors on matrilysin-induced tumor cell aggregation. Monensin, which inhibits the transport of secretory proteins and membrane proteins, and cytochalasin-B (inhibitor of actin polymerization) did not affect the initial cell aggregation but completely blocked the stable aggregation (data not shown). This suggested that the intracellular transport of E-cadherin and the E-cadherin-mediated cytoskeletal change might be required for the stable aggregation. Our results do not exclude the possibility that elevated degradation of E-cadherin plays an important role in some steps of tumor invasion or metastasis. Regarding tumor cell aggregation, however, some antiadhesive proteins, for example, MUC-1 (Kondo et al., 1998) and podocalyxin (Takeda et al., 2000) , rather than cell adhesion proteins may be important substrates of matrilysin. The The present study also demonstrated that the direct matrilysin treatment of colon carcinoma cells enhanced their metastatic ability in an experimental metastasis model of WiDr cells with nude mice. WiDr cells, which grow as multicellular spheroids in nonadherent plastic plates (Monz et al., 1996) , have been shown to be a good in vitro model for studying responses of cancer cells to drugs and irradiation (Inch et al., 1970; Olive and Banath, 1997) . The culture of three-dimensional compact multicellular aggregates is believed to mimic in vivo conditions more closely than the two-dimensional monolayer culture (Mueller-Klieser, 1997) . We have previously shown using WiDr cells that an antisense oligonucleotide to matrilysin efficiently inhibits their liver metastasis (Hasegawa et al., 1998) . In the present study, matrilysin-treated WiDr cells in the stable multicellular aggregates, but not those in the initial loose aggregates, showed resistance to cell death in the anchorage-independent serum-free culture conditions and highly metastasized to the liver in vivo. Past studies have shown the correlation between tumorigenicity and growth ability in suspension culture. Cultured cells, especially normal cells, undergo apoptosis in the anchorage-independent conditions, because they cannot receive signals for cell growth from ECM proteins through integrins. E-cadherin is required for the anchorage-independent survival and growth of tumor cells (Kantak and Kramer, 1998; Mueller et al., 2000) . This was shown in the anchorage-independent survival of WiDr cells in the E-cadherin-mediated stable aggregates in this study. Thus, the anchorage-independent cell survival ability enhanced by matrilysin treatment may be one possible mechanism for the increased metastatic ability in vivo. Alternatively, the formation of emboli of tumor cell spheroids in blood vessels may facilitate the lodging and subsequent growth of tumor cells in the peripheral tissues. Furthermore, the spheroid organization may play a role in the defense from the immune system.
The present study proposes a new mechanism that tumor cell-derived matrilysin not only degrades ECM proteins but also binds to and acts on the tumor cell membrane in an autocrine mechanism, thus enhancing their metastatic capacity.
Materials and methods
Cell lines and culture conditions
Human colon cancer cell lines WiDr (Noguchi et al., 1979) and Colo201 (Semple et al., 1978) were obtained from the Japanese Cancer Resources Bank. They were maintained in Dulbecco's modified Eagle's medium (DMEM)/F12 medium (DMEM/ FR) (Life Technologies, Inc., Grand Island, NY, USA) supplemented with 10% FBS. Colo201 grew in suspension.
Antibodies and other reagents
The anti-human matrilysin mouse monoclonal antibody 11B4G was a kind gift from Dr Y Matuo (Nagahama Institute of Oriental Yeast Co., Shiga, Japan). The anti-E-cadherin mouse monoclonal antibody was purchased from Zymed Laboratories (San Francisco, CA, USA). The synthetic MMP inhibitor KB8301 was purchased from Pharmingen (San Diego, CA, USA), and TAPI-1 was from Peptides International (Louisville, KY, USA). Human recombinant matrilysin was purchased from Wako Pure Chemical Industries (Osaka, Japan). Human gelatinase A, human TIMP-2, and rat stromelysin were purified in this laboratory, as described previously Higashi and Miyazaki, 1999) .
Assay of matrilysin binding to cell membrane
The binding of matrilysin to tumor cell membrane was analysed by Western blotting of the membrane fraction. Colo 201 cells (1 Â 10 6 ) in serum-free DMEM/F12 were incubated with or without matrilysin for indicated lengths of time. The cells were collected, washed two times with phosphate-buffered saline (PBS), homogenized in 1 ml of 20 mM HEPES buffer (pH 7.5) containing 250 mM sucrose with a Potter-type homogenizer. The homogenate was centrifuged at 800 g for 7 min to remove nuclei and cellular debris. The postnuclear supernatant was centrifuged at 21 000 g for 1 h, and the resulting precipitate was used as the cell membrane. The membrane fraction was separated on 14% or 4-20% polyacrylamide gels by SDS-PAGE under reducing conditions. After the electrophoresis, proteins were electrophoretically transferred onto nitrocellulose membranes. The blotted membrane was blocked with PBS-containing 5% skim milk at room temperature overnight, and then reacted with the antimatrilysin antibody 11B4G for 3 h. Immunoreactive signal was visualized by the alkaline phosphatase method.
Cell aggregation assay
WiDr or Colo201 cells (1 Â 10 6 cells) were plated on poly-HEMA-coated 35-mm dishes in the serum-free medium. To observe cell aggregation, the cells were incubated with human recombinant active matrilysin (1 mg/ml) in the presence or absence of various MMP inhibitors. The degree of cell aggregation was quantified by the following equation (Inohara et al., 1996) : (1ÀNt/Nc) Â 100, where Nt (test) and Nc (control) represent the number of single cells in the presence or absence of a test sample, respectively. To discriminate between initial loose aggregation and subsequently formed stable aggregation, these cell aggregates received 10 times pipetting with equivalent force before counting single cells.
Immunofluorescence staining E-cadherin and matrilysin on cell surface were visualized with fluorescence. Colo 201 cells that had been treated with matrilysin (1 mg/ml) for 3 h or 24 h were collected onto plastic plates using suspension cell-harvesting packets (Tommy, Tokyo, Japan), fixed with 10% formaldehyde for 15 min, and washed three times with PBS. After blocking with 1% bovine serum albumin (BSA) in PBS, the cells were sequentially incubated with an anti-E-cadherin monoclonal antibody ( Â 100), with a biotin-conjugated second antibody, and then with FITC-avidin D. To detect the binding of matrilysin to cell surface, cells were treated with biotinylated matrilysin (1 mg/ ml) and visualized with FITC-avidin D.
Cell survival assay
To examine cell viability in suspension culture, matrilysintreated WiDr cells (5 Â 10 5 cells) were cultured in 35-mm poly-HEMA-coated dishes containing 1.5% methylcellulose in DMEM/F12. Monolayer cell growth was assayed in the poly-HEMA-coated dishes with the serum-free medium. The relative cell number was determined with a colorimetric MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-terazolium]/PMS (phenazine methosulfate) cell proliferation assay kit. Test cultures were incubated with the dye for 4 h and then the absorbance at 490 nm was recorded for each dish.
Experimental metastasis of colon carcinoma cells in nude mice
WiDr cells were harvested with trypsin/EDTA and suspended in DME/F12 containing 10% FBS. After washing three times with serum-free DME/F12, cells were incubated with matrilysin (1 mg/ml) or an equal volume of PBS as control for 3 or 24 h. The cells were collected, washed three times with DMEM/F12 and suspended in 100 ml of DMEM/F12 containing 10% FBS. The cell suspension was injected slowly into the spleen of pathogen-free BALB/c nu/nu athymic mice (5 Â 10 6 cells/mice). After 20-22 days, the animals were klilled, and the number and size of metastatic tumor foci in the livers were measured.
